Search

Gadoteridol

[A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained

Miocamycin

or as an alternative to erythromycin treatment [A176170]. … This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737].

Deutetrabenazine

It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. … Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission [A14081].

Crotamiton

Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor.

Maralixibat

[A239249] Surgical interventions such as partial external bile diversion and ileal exclusion have also been used as treatments. … It was granted FDA approval on 29 September 2021.

Unoprostone

Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate. The main indication of Unoprostane is treatment of glucoma.

L-Glutamine

An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.

Calcium glucoheptonate

Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium.

Botulinum toxin type A

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use.

Acetate